Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
2023-05-14
May 14 (Reuters) - Drugmaker Athenex Inc (ATNX.O) and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings, the company said on Sunday.
Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets, the company said in a statement.
The Buffalo, New York-based company has listed estimated assets and liabilities in the range of $100 million-$500 million, according to a filing with the U.S. Bankruptcy Court for the Southern District of Texas.
The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, the company said, adding that it expects the expedited process to be completed by July 1, 2023.
The company said it has sufficient resources to support Athenex Pharma Solutions operations, and fulfill APD customer orders during the sale process.
Our Standards: The Thomson Reuters Trust Principles.
Preview
来源: Reuters
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
-靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。